---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-26-000006"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:35:52.512817+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# iBio reports IBIO-610 reduces visceral fat 6.7%, total fat 5.2% in obese NHPs; expands into cardiopulmonary

## Summary
- Preclinical study: IBIO-610 reduced visceral fat by 6.7% and total fat mass by 5.2% after two doses every 8 weeks.
- Extended half-life of 33.2 days in NHPs; projected human half-life up to 100 days suggesting twice-yearly dosing.
- Company announces strategic expansion into cardiopulmonary space, targeting PH-HFpEF with myostatin x Activin A bispecific.
- Data consistent with other Activin E pathway approaches; full dataset to be presented at scientific conferences in 2026.

## SEC filing metadata
- accession: 0001420720-26-000006
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000006/0001420720-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000006/ibio-20260309x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-26-000006
- JSON: https://secwatch.observer/filing/0001420720-26-000006.json
- Plain text: https://secwatch.observer/filing/0001420720-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.